Unveiling the promise: Exosomes as game‐changers in anti‐infective therapy

Abstract

Extracellular vesicles (EVs)‐based intercellular communication (through exosomes, microvesicles, and apoptotic bodies) is conserved across all kingdoms of life. In recent years, exosomes have gained much attention for targeted pharmaceutical administration due to their unique features, nanoscale size, and capacity to significantly contribute to cellular communication. As drug delivery vehicles, exosomes have several advantages over alternative nanoparticulate drug delivery technologies. A key advantage lies in their comparable makeup to the body's cells, which makes them non‐immunogenic. However, exosomes vesicles face several challenges, including a lack of an effective and standard production technique, decreased drug loading capacity, limited characterization techniques, and underdeveloped isolation and purification procedures. Exosomes are well known for their long‐term safety and natural ability to transport intercellular nucleic acids and medicinal compounds across the blood‐brain‐barrier (BBB). Therefore, in addition to revealing new insights into exosomes’ distinctiveness, the growing availability of new analytical tools may drive the development of next‐generation synthetic systems. Herein, light is shed on exosomes as drug delivery vehicles in anti‐infective therapy by reviewing the literature on primary articles published between 2002 and 2023. Additionally, the benefits and limitations of employing exosomes as vehicles for therapeutic drug delivery are also discussed.